BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 37707754)

  • 1. Somatostatin receptor subtype expression and radiomics from DWI-MRI represent SUV of [68Ga]Ga-DOTATOC PET in patients with meningioma.
    Iglseder S; Iglseder A; Beliveau V; Heugenhauser J; Gizewski ER; Kerschbaumer J; Stockhammer G; Uprimny C; Virgolini I; Dudas J; Nevinny-Stickel M; Nowosielski M; Scherfler C
    J Neurooncol; 2023 Sep; 164(3):711-720. PubMed ID: 37707754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Semi-automated segmentation methods of SSTR PET for dosimetry prediction in refractory meningioma patients treated by SSTR-targeted peptide receptor radionuclide therapy.
    Boursier C; Zaragori T; Bros M; Bordonne M; Melki S; Taillandier L; Blonski M; Roch V; Marie PY; Karcher G; Imbert L; Verger A
    Eur Radiol; 2023 Oct; 33(10):7089-7098. PubMed ID: 37148355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment-related changes in neuroendocrine tumors as assessed by textural features derived from
    Weber M; Kessler L; Schaarschmidt B; Fendler WP; Lahner H; Antoch G; Umutlu L; Herrmann K; Rischpler C
    BMC Cancer; 2020 Apr; 20(1):326. PubMed ID: 32299391
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Mapelli P; Bezzi C; Palumbo D; Canevari C; Ghezzo S; Samanes Gajate AM; Catalfamo B; Messina A; Presotto L; Guarnaccia A; Bettinardi V; Muffatti F; Andreasi V; Schiavo Lena M; Gianolli L; Partelli S; Falconi M; Scifo P; De Cobelli F; Picchio M
    Eur J Nucl Med Mol Imaging; 2022 Jun; 49(7):2352-2363. PubMed ID: 35156146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of 68Ga-DOTATOC PET/MRI on robotic radiosurgery treatment planning in meningioma patients: first experiences in a single institution.
    Acker G; Kluge A; Lukas M; Conti A; Pasemann D; Meinert F; Anh Nguyen PT; Jelgersma C; Loebel F; Budach V; Vajkoczy P; Furth C; Baur ADJ; Senger C
    Neurosurg Focus; 2019 Jun; 46(6):E9. PubMed ID: 31153151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas.
    Henze M; Schuhmacher J; Hipp P; Kowalski J; Becker DW; Doll J; Mäcke HR; Hofmann M; Debus J; Haberkorn U
    J Nucl Med; 2001 Jul; 42(7):1053-6. PubMed ID: 11438627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET.
    Milker-Zabel S; Zabel-du Bois A; Henze M; Huber P; Schulz-Ertner D; Hoess A; Haberkorn U; Debus J
    Int J Radiat Oncol Biol Phys; 2006 May; 65(1):222-7. PubMed ID: 16488553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of the apparent diffusion coefficient with the standardized uptake value in meningioma of the skull plane using [68]Ga-DOTATOC PET/MRI.
    Milosevic A; Styczen H; Haubold J; Kessler L; Grueneisen J; Li Y; Weber M; Fendler WP; Morawitz J; Damman P; Wrede K; Kebir S; Glas M; Guberina M; Blau T; Schaarschmidt BM; Deuschl C
    Nucl Med Commun; 2023 Dec; 44(12):1106-1113. PubMed ID: 37823259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 68Ga-DOTATOC and FDG PET Imaging of Preclinical Neuroblastoma Models.
    Provost C; Prignon A; Cazes A; Combaret V; Delattre O; Janoueix-Lerosey I; Montravers F; Talbot JN
    Anticancer Res; 2016 Sep; 36(9):4459-66. PubMed ID: 27630282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The trends and significance of SSTR PET/CT added to MRI in follow-up imaging of low-grade meningioma treated with fractionated proton therapy.
    Lütgendorf-Caucig C; Pelak M; Flechl B; Georg P; Fossati P; Stock M; Traub-Weidinger T; Marosi C; Haberler C; Zechmeister-Machhart G; Hermsmeyer L; Hug E; Staudenherz A
    Strahlenther Onkol; 2023 Apr; 199(4):396-403. PubMed ID: 36260109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.
    Putzer D; Kroiss A; Waitz D; Gabriel M; Traub-Weidinger T; Uprimny C; von Guggenberg E; Decristoforo C; Warwitz B; Widmann G; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):364-72. PubMed ID: 23151915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of cranial meningiomas: comparison of ⁶⁸Ga-DOTATOC PET/CT and contrast-enhanced MRI.
    Afshar-Oromieh A; Giesel FL; Linhart HG; Haberkorn U; Haufe S; Combs SE; Podlesek D; Eisenhut M; Kratochwil C
    Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1409-15. PubMed ID: 22669255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic analysis of [
    Bashir A; Vestergaard MB; Binderup T; Broholm H; Marner L; Ziebell M; Fugleholm K; Mathiesen T; Kjær A; Law I
    Eur J Nucl Med Mol Imaging; 2020 Oct; 47(11):2577-2588. PubMed ID: 32170347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meningiomas: a comparative study of 68Ga-DOTATOC, 68Ga-DOTANOC and 68Ga-DOTATATE for molecular imaging in mice.
    Soto-Montenegro ML; Peña-Zalbidea S; Mateos-Pérez JM; Oteo M; Romero E; Morcillo MÁ; Desco M
    PLoS One; 2014; 9(11):e111624. PubMed ID: 25369268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ⁶⁸Ga-DOTA⁰-Tyr³-octreotide positron emission tomography in head and neck squamous cell carcinoma.
    Schartinger VH; Dudás J; Decristoforo C; Url C; Schnabl J; Göbel G; Virgolini IJ; Riechelmann H; Rasse M; Waitz D; Putzer D
    Eur J Nucl Med Mol Imaging; 2013 Sep; 40(9):1365-72. PubMed ID: 23685751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
    Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
    J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results.
    Beiderwellen KJ; Poeppel TD; Hartung-Knemeyer V; Buchbender C; Kuehl H; Bockisch A; Lauenstein TC
    Invest Radiol; 2013 May; 48(5):273-9. PubMed ID: 23493121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contribution of 68Ga-DOTATOC PET/CT to target volume delineation of skull base meningiomas treated with stereotactic radiation therapy.
    Graf R; Nyuyki F; Steffen IG; Michel R; Fahdt D; Wust P; Brenner W; Budach V; Wurm R; Plotkin M
    Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):68-73. PubMed ID: 22575489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous 68Ga-DOTATOC-PET/MRI for IMRT treatment planning for meningioma: first experience.
    Thorwarth D; Henke G; Müller AC; Reimold M; Beyer T; Boss A; Kolb A; Pichler B; Pfannenberg C
    Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):277-83. PubMed ID: 21300465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of [
    Milosevic A; Styczen H; Grueneisen J; Li Y; Weber M; Fendler WP; Kirchner J; Damman P; Wrede K; Lazaridis L; Glas M; Guberina M; Eckstein A; Blau T; Herrmann K; Umutlu L; Forsting M; Deuschl C; Schaarschmidt B
    J Nucl Med; 2023 Aug; 64(8):1185-1190. PubMed ID: 37385668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.